ArticleBMC gastroenterology2026
Intra-abdominal aggressive fibromatosis: a single-center case series of 12 patients focusing on surgical management and clinicopathological features.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntra-abdominal aggressive fibromatosis (AF) is a rare disease with invasive growth and local recurrence. However, few studies have reported the clinical and pathological features of intra-abdominal AF. The aim of this study is to systematically elucidate the clinical characteristics, imaging manifestations, treatment and pathological features of intra-abdominal AF.
methodsA total of 12 patients with intra-abdominal AF diagnosed in Xijing Hospital, First Affiliated Hospital of Air Force Medical University from April 2021 to September 2024 were included. All the specimens underwent routine staining and immunohistochemical analysis. The study was approved by the Ethics Review Committee of Xijing hospital.
resultsA total of 12 patients with intra-abdominal AF were enrolled (median age: 33 years; range: 16–59 years). Tumors were located in the retroperitoneum (n = 8) or small intestinal mesentery (n = 4), with a mean maximum diameter of 9 cm (6–30 cm). Computed tomography typically showed irregular soft tissue masses with heterogeneous density and enhancement. All patients underwent R0 resection; notably, 10 (83.3%) required combined organ resection due to involvement of adjacent organs or major vessels. Postoperatively, four patients (33.3%) developed mild, transient complications, all of which resolved with conservative management during the same hospitalization. No adjuvant therapy was administered. Immunohistochemistry revealed nuclear β-catenin positivity in all 12 cases (100%), SMA positivity in seven (58.3%), Vimentin positivity in four (33.3%), and a Ki-67 index of 2–20%. CD117 was negative in all cases. At a median follow-up of 23 months (7–48 months), no recurrence or metastasis was observed.
conclusionIntra-abdominal AF is a rare disease with a high reported local recurrence rate. Early surgery can achieve complete removal in experienced medical centers, and complication rates are acceptable, with good short-term prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.